Literature DB >> 10472149

A multi-attribute model of prostate cancer patient's preferences for health states.

G B Chapman1, A S Elstein, T M Kuzel, R B Nadler, R Sharifi, C L Bennett.   

Abstract

Multi-attribute utility theory (MAUT) provides a way to model decisions involving trade-offs among different aspects or goals of a problem. We used MAUT to model prostate cancer patients' preferences for their own health state and we compared this model to patients' global judgments of health state utility. 57 patients with prostate cancer (mean age = 70) at two Chicago Veterans Administration health clinics were asked to evaluate health states described in terms of five health attributes affected by prostate cancer: pain, mood, sexual function, bladder and bowel function, and fatigue and energy. Each attribute had three levels that were used to form three clinically realistic health state descriptions (A = high, B = moderate, C = low). A fourth personalized health description (P) matched the patient's current health. We first measured patients' preferences using time trade-off (TTO) judgments for the three health states (A, B, and C) and for their own current health state (P). The TTO for the patient's own health state (P) was standardized by comparing it to TTO judgments for states A and C. We next constructed a multi-attribute model using the relative importance of the five attributes. The MAU scores were moderately correlated with the TTO preference judgments for the personalized state (Pearson r = 0.38, N = 57, p < 0.01). Thus, patients' preference judgments are moderately consistent and systematic. MAUT appears to be a potentially feasible method for evaluating preferences of prostate cancer patients and may prove helpful in assisting with patient decision making.

Entities:  

Mesh:

Year:  1999        PMID: 10472149     DOI: 10.1023/a:1008850610569

Source DB:  PubMed          Journal:  Qual Life Res        ISSN: 0962-9343            Impact factor:   4.147


  22 in total

1.  Tradeoffs between quality and quantity of life: development of the QQ Questionnaire for Cancer Patient Attitudes.

Authors:  A M Stiggelbout; J C de Haes; G M Kiebert; J Kievit; J W Leer
Journal:  Med Decis Making       Date:  1996 Apr-Jun       Impact factor: 2.583

Review 2.  Utility approach to measuring health-related quality of life.

Authors:  G W Torrance
Journal:  J Chronic Dis       Date:  1987

3.  Comparison of physicians' decisions regarding estrogen replacement therapy for menopausal women and decisions derived from a decision analytic model.

Authors:  A S Elstein; G B Holzman; M M Ravitch; W A Metheny; M M Holmes; R B Hoppe; M L Rothert; D R Rovner
Journal:  Am J Med       Date:  1986-02       Impact factor: 4.965

4.  The "utility" of the Time Trade-Off method in cancer patients: feasibility and proportional Trade-Off.

Authors:  A M Stiggelbout; G M Kiebert; J Kievit; J W Leer; J D Habbema; J C De Haes
Journal:  J Clin Epidemiol       Date:  1995-10       Impact factor: 6.437

5.  A multiattribute-utility-function approach to weighing the risks and benefits of pharmaceutical agents.

Authors:  S Eriksen; L R Keller
Journal:  Med Decis Making       Date:  1993 Apr-Jun       Impact factor: 2.583

6.  A comparison of perspectives on prostate cancer: analysis of utility assessments of patients and physicians.

Authors:  C L Bennett; G Chapman; A S Elstein; S J Knight; R B Nadler; R Sharifi; T Kuzel
Journal:  Eur Urol       Date:  1997       Impact factor: 20.096

7.  Evaluating the quality of life associated with rifabutin prophylaxis for Mycobacterium avium complex in persons with AIDS: combining Q-TWiST and multiattribute utility techniques.

Authors:  D A Revicki; K N Simpson; A W Wu; R L LaVallee
Journal:  Qual Life Res       Date:  1995-08       Impact factor: 4.147

8.  Parents' versus physicians' values for clinical outcomes in young febrile children.

Authors:  M S Kramer; J Etezadi-Amoli; A Ciampi; S M Tange; K N Drummond; E L Mills; M L Bernstein; D G Leduc
Journal:  Pediatrics       Date:  1994-05       Impact factor: 7.124

9.  Quality of life after radical retropubic prostatectomy for carcinoma of the prostate.

Authors:  K V Pedersen; P Carlsson; M Rahmquist; E Varenhorst
Journal:  Eur Urol       Date:  1993       Impact factor: 20.096

10.  Multiattribute utility assessment of outcomes of treatment for head and neck cancer.

Authors:  S C Hodder; M J Edwards; M R Brickley; J P Shepherd
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

View more
  5 in total

1.  A Randomized Controlled Trial of Strategies to Improve Family Members' Preparedness for Surrogate Decision-Making.

Authors:  Michael J Green; Lauren J Van Scoy; Andrew J Foy; Renee R Stewart; Ramya Sampath; Jane R Schubart; Erik B Lehman; Anne E F Dimmock; Ashley M Bucher; Lisa S Lehmann; Alyssa F Harlow; Chengwu Yang; Benjamin H Levi
Journal:  Am J Hosp Palliat Care       Date:  2017-11-29       Impact factor: 2.500

Review 2.  "I can't afford that!": dilemmas in the care of the uninsured and underinsured.

Authors:  S Weiner
Journal:  J Gen Intern Med       Date:  2001-06       Impact factor: 5.128

3.  A randomized study comparing epirubicin in a 4-weekly versus a weekly intravenous regimen in patients with metastatic, hormone resistant, prostatic carcinoma: effects on health related quality of life.

Authors:  G van Andel; P Fernandez de Moral; C T M Caris; P Carpentier; J Wils; M J F M de Bruin; J A Witjes; F M J Debruyne; W P J Witjes
Journal:  World J Urol       Date:  2003-06-18       Impact factor: 4.226

4.  Evaluating the relationship between pain presentation and health-related quality of life in outpatients with metastatic or recurrent neoplastic disease.

Authors:  J E Owen; J C Klapow; L Casebeer
Journal:  Qual Life Res       Date:  2000       Impact factor: 3.440

5.  Survival gains needed to offset persistent adverse treatment effects in localised prostate cancer.

Authors:  M T King; R Viney; D P Smith; I Hossain; D Street; E Savage; S Fowler; M P Berry; M Stockler; P Cozzi; P Stricker; J Ward; B K Armstrong
Journal:  Br J Cancer       Date:  2012-01-24       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.